Agilent will showcase the Cary 3500 UV-Vis system at analytica China, being held October 31 November 2, 2018, in Shanghai, China.
Global growth in the development of biological drugs is leading to the evolution of many new biological entities.
Before these NBEs are adapted into therapeutics, laboratories must accurately characterize each new product and continuously monitor the quality of these products throughout the development process.
According to the company, the new system enables laboratories to make substantial gains in efficiency as it can run multiple experiments simultaneously, allowing labs to obtain more results in the same amount of time--and it also extends the opportunity to design experiments in ways that have not been possible before.
The Cary 3500 harnesses the power of a state-of-the-art software platform and a fast and powerful Xenon flash lamp that is redefining UV-Vis spectrophotometry.
Indeed, the system's rapid, accurate, temperature control permits temperature experiments at ramp rates previously thought to be unattainable, providing more reliable and robust measurements.
Agilent Technologies Inc. (NYSE: A) is a leader in life sciences, diagnostics, and applied chemical markets.
With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions.
The company generated revenues of USD 4.47bn in fiscal 2017 and employs 14,500 people worldwide.
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption